These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 19543143)

  • 21. The value of male human papillomavirus vaccination in preventing cervical cancer and genital warts in a low-resource setting.
    Sharma M; Sy S; Kim JJ
    BJOG; 2016 May; 123(6):917-26. PubMed ID: 26176301
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of genital warts: loss of quality of life and cost of treatment in eight sexual health clinics in the UK.
    Woodhall SC; Jit M; Soldan K; Kinghorn G; Gilson R; Nathan M; Ross JD; Lacey CJ;
    Sex Transm Infect; 2011 Oct; 87(6):458-63. PubMed ID: 21636616
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The cost-effectiveness of male HPV vaccination in the United States.
    Chesson HW; Ekwueme DU; Saraiya M; Dunne EF; Markowitz LE
    Vaccine; 2011 Oct; 29(46):8443-50. PubMed ID: 21816193
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Economic evaluation of human papillomavirus vaccination in the United Kingdom.
    Jit M; Choi YH; Edmunds WJ
    BMJ; 2008 Jul; 337():a769. PubMed ID: 18640957
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Significant decline of HPV 6 infection and genital warts despite low HPV vaccination coverage in young women in Germany: a long-term prospective, cohort data analysis.
    Denecke A; Iftner T; Iftner A; Riedle S; Ocak M; Luyten A; Üye I; Tunc K; Petry KU
    BMC Infect Dis; 2021 Jul; 21(1):634. PubMed ID: 34215215
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of anogenital warts on health-related quality of life: a 6-month prospective study.
    Drolet M; Brisson M; Maunsell E; Franco EL; Coutlée F; Ferenczy A; Ratnam S; Fisher W; Mansi JA
    Sex Transm Dis; 2011 Oct; 38(10):949-56. PubMed ID: 21934571
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of the human papillomavirus (HPV) vaccine on genital wart diagnoses at Auckland Sexual Health Services.
    Oliphant J; Perkins N
    N Z Med J; 2011 Jul; 124(1339):51-8. PubMed ID: 21952330
    [TBL] [Abstract][Full Text] [Related]  

  • 28. What can surveillance of genital warts tell us?
    Fairley CK; Donovan B
    Sex Health; 2010 Sep; 7(3):325-7. PubMed ID: 20719222
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK.
    Dasbach EJ; Insinga RP; Elbasha EH
    BJOG; 2008 Jul; 115(8):947-56. PubMed ID: 18503574
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness and equity impacts of three HPV vaccination programmes for school-aged girls in New Zealand.
    Blakely T; Kvizhinadze G; Karvonen T; Pearson AL; Smith M; Wilson N
    Vaccine; 2014 May; 32(22):2645-56. PubMed ID: 24662710
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost analysis of Human Papillomavirus-related cervical diseases and genital warts in Swaziland.
    Ginindza TG; Sartorius B; Dlamini X; Östensson E
    PLoS One; 2017; 12(5):e0177762. PubMed ID: 28531205
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Annual prevalence and economic burden of genital warts in Korea: Health Insurance Review and Assessment (HIRA) service data from 2007 to 2015.
    Park YJ; Kim JM; Lee BR; Kim TH; Lee EG
    Epidemiol Infect; 2018 Jan; 146(2):177-186. PubMed ID: 29235433
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reducing the health burden of HPV infection through vaccination.
    Soper D
    Infect Dis Obstet Gynecol; 2006; 2006 Suppl():83084. PubMed ID: 16967913
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Appraisal of the burden of genital warts from a healthcare and individual patient perspective.
    Scarbrough Lefebvre CD; Van Kriekinge G; Gonçalves MA; de Sanjose S
    Public Health; 2011 Jul; 125(7):464-75. PubMed ID: 21722930
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada.
    Brisson M; Van de Velde N; De Wals P; Boily MC
    Vaccine; 2007 Jul; 25(29):5399-408. PubMed ID: 17561316
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human papillomavirus vaccination and genital warts in young Indigenous Australians: national sentinel surveillance data.
    Ali H; McManus H; O'Connor CC; Callander D; Kong M; Graham S; Saulo D; Fairley CK; Regan DG; Grulich A; Low N; Guy RJ; Donovan B
    Med J Aust; 2017 Mar; 206(5):204-209. PubMed ID: 28301790
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost–effectiveness of catch-up programs in human papillomavirus vaccination.
    de Peuter MA; Littlewood KJ; Annemans L; Largeron N; Quilici S
    Expert Rev Vaccines; 2010 Oct; 9(10):1187-201. PubMed ID: 20923269
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reductions in human papillomavirus-disease resource use and costs with quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccination: the FUTURE Study Economic Evaluation.
    Insinga RP; Dasbach EJ; Allen SE; Carides GW; Myers ER
    Value Health; 2008 Dec; 11(7):1022-32. PubMed ID: 18489503
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
    McCormack PL; Joura EA
    BioDrugs; 2011 Oct; 25(5):339-43. PubMed ID: 21942919
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The costs of managing genital warts in the UK by devolved nation: England, Scotland, Wales and Northern Ireland.
    Coles VA; Chapman R; Lanitis T; Carroll SM
    Int J STD AIDS; 2016 Jan; 27(1):51-7. PubMed ID: 25681263
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.